https://www.pharmaradar360.com/article/35ac4009636c94dfPharmaRadar360en2026-05-07T09:44:00.000ZThe Danish Medicines Agency will be closed on Friday 15 May 2026https://www.pharmaradar360.com/article/f703dd2134e88db7PharmaRadar360en2026-05-07T09:38:57.000ZΑνάκληση των παρτίδων 20256508 και 202510501 των ιατροτεχνολογικών προϊόντων δοχεία συλλογής αίματος Lab tub Blood Collections Tubes 9NC Sodium Citrate, 13X75mm, 4mlhttps://www.pharmaradar360.com/article/3598afd6ecee704dPharmaRadar360en2026-05-07T09:35:21.000ZΑνάκληση της παρτίδας 25F1340 (exp date 12/2026) του ιατροτεχνολογικού προϊόντος δοχεία συλλογής αίματος VACUMED with K2 EDTA 16.2 mg Blood Collections Tubes 16X100 mm, 9ml (μωβ πώμα)https://www.pharmaradar360.com/article/080c22ea8c9f0b8dPharmaRadar360en2026-05-07T09:17:00.000ZOperation Pangea XVIII: Global action against falsified medicines and illicit tradehttps://www.pharmaradar360.com/article/6485a7b12ebe7ea9PharmaRadar360en2026-05-07T06:50:44.000ZΑπαγόρευση διακίνησης και διάθεσης του προϊόντος ASEPTOMAN GELhttps://www.pharmaradar360.com/article/382c1fda54d84a5aPharmaRadar360en2026-05-07T05:00:00.000ZRoche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnosticshttps://www.pharmaradar360.com/article/fc52d2c6db4b440dPharmaRadar360en2026-05-07T00:00:00.000ZSysmex Included in S&P Dow Jones Indices’ Global ESG Index for the 10th Consecutive Yearhttps://www.pharmaradar360.com/article/eaac1e4733ff3bcePharmaRadar360en2026-05-07T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/1afe38d728ab2c25PharmaRadar360en2026-05-07T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/abba2096d856d4ddPharmaRadar360en2026-05-07T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/5d5d5a2912ab86a4PharmaRadar360en2026-05-07T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/4a98a645a03bd2b0PharmaRadar360en2026-05-07T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/e136a620f89514e1PharmaRadar360en2026-05-07T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/087b5f9eb03834a6PharmaRadar360en2026-05-07T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/01483c983ac4ad86PharmaRadar360en2026-05-07T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/59637e5d5a5edc98PharmaRadar360en2026-05-07T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/48ef7c5306101c43PharmaRadar360en2026-05-07T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/6cf3e12fed6b8764PharmaRadar360en2026-05-07T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/04e490ba54365926PharmaRadar360en2026-05-07T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/86474ea8d2389760PharmaRadar360en2026-05-07T00:00:00.000Z6203https://www.pharmaradar360.com/article/43e5f3222a09430aPharmaRadar360en2026-05-07T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/56398c3e58113422PharmaRadar360en2026-05-06T18:51:56.000ZWhat Continuous Trials Could Mean for Clinical Data Standards and Oversighthttps://www.pharmaradar360.com/article/af103ac34523ae6fPharmaRadar360en2026-05-06T18:38:01.000ZFifarma Annual Summit 2026 define roteiro para acelerar o acesso à inovação em saúde na América Latinahttps://www.pharmaradar360.com/article/f7ad488e2dcb6398PharmaRadar360en2026-05-06T17:57:38.000ZFinding a Way Forward: How the National MPS Society’s Pathways Program Supports Families at Diagnosishttps://www.pharmaradar360.com/article/bf54e22e58d8d168PharmaRadar360en2026-05-06T16:00:00.000ZChina med-tech raises: Star Sports’ $105M IPO; Cofoe nabs $133Mhttps://www.pharmaradar360.com/article/0abd5e53f7850086PharmaRadar360en2026-05-06T16:00:00.000ZMultiple appearances on Priority Watch List leading to action?https://www.pharmaradar360.com/article/f02d4fcd6d2c8922PharmaRadar360en2026-05-06T15:12:21.000ZEMULIQUEN LAXANTE, varias presentacioneshttps://www.pharmaradar360.com/article/b8a675c41980190dPharmaRadar360en2026-05-06T14:49:58.000ZWTR podcast: Unlocking Hard-to-Scale Molecules with AI-Driven, Cell-Free Biomanufacturinghttps://www.pharmaradar360.com/article/c77518b80e57ed87PharmaRadar360en2026-05-06T14:08:58.000ZLa AEMPS inicia los IPT de los medicamentos que han obtenido una opinión positiva en la reunión del CHMP celebrada en marzohttps://www.pharmaradar360.com/article/cb1282c56c577ed4PharmaRadar360en2026-05-06T13:00:00.000ZSimcere Zaiming’s SIM-0613 cleared to enter clinic in Chinahttps://www.pharmaradar360.com/article/4793e159bd719695PharmaRadar360en2026-05-06T13:00:00.000ZLilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facilityhttps://www.pharmaradar360.com/article/6efb77b901ce02faPharmaRadar360en2026-05-06T12:59:29.000ZExport drugs and medicines: special ruleshttps://www.pharmaradar360.com/article/a9ae56c261edff0ePharmaRadar360en2026-05-06T12:00:00.000ZGSK presents latest respiratory research to advance patient care at ATS 2026https://www.pharmaradar360.com/article/cfcb025e876cb770PharmaRadar360en2026-05-06T12:00:00.000ZAbbVie to Present at the Bank of America Securities Healthcare Conferencehttps://www.pharmaradar360.com/article/78c0e4750df4a895PharmaRadar360en2026-05-06T11:56:20.000ZClinical investigations for medical deviceshttps://www.pharmaradar360.com/article/642f464f4458d798PharmaRadar360en2026-05-06T11:00:00.000ZRelmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026https://www.pharmaradar360.com/article/c67872f2a44f0cf8PharmaRadar360en2026-05-06T10:59:00.000ZBristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026https://www.pharmaradar360.com/article/c19c55cf7eda6eebPharmaRadar360en2026-05-06T09:26:28.000ZΕγκύκλιος SUNSET CLAUSEhttps://www.pharmaradar360.com/article/77a2c151edb11abfPharmaRadar360en2026-05-06T07:54:27.000ZField Safety Notices: 1 May 2026https://www.pharmaradar360.com/article/53f5a1efeb03e3d4PharmaRadar360en2026-05-06T07:00:23.000ZLa AEMPS inicia su colaboración con la Agencia Africana del Medicamento (AMA)https://www.pharmaradar360.com/article/60a418171ab76943PharmaRadar360en2026-05-06T06:01:19.000ZAvacta presents new comparisons of pre|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026https://www.pharmaradar360.com/article/a06290eac658b8e9PharmaRadar360en2026-05-06T04:21:52.000ZΓενόσημα Φεβρουαρίου 2026_Τελικές Προτεινόμενες Τιμέςhttps://www.pharmaradar360.com/article/4ad376d2b0cce5b0PharmaRadar360en2026-05-06T01:36:27.000ZResearch Rising Starts with Peoplehttps://www.pharmaradar360.com/article/e0723cdfd19aaf01PharmaRadar360en2026-05-06T01:18:16.000Z1087 2https://www.pharmaradar360.com/article/e50f7751aeb851ebPharmaRadar360en2026-05-06T00:00:00.000ZTips for Dealing with Restless Legs Syndromehttps://www.pharmaradar360.com/article/050e5fd3cd5d646bPharmaRadar360en2026-05-06T00:00:00.000ZCleveland Clinic Children’s Derby Soirée Raises More Than $6.5 Million to Support Pediatric Care and Researchhttps://www.pharmaradar360.com/article/a7661dd486fc2c01PharmaRadar360en2026-05-06T00:00:00.000ZUnited Therapeutics Corporation Reports First Quarter 2026 Financial Resultshttps://www.pharmaradar360.com/article/d5fecfb31fc103d3PharmaRadar360en2026-05-05T22:08:49.000ZComo llegar a la Juntahttps://www.pharmaradar360.com/article/2d799ad658bab939PharmaRadar360en2026-05-05T22:07:49.000ZSolicitudes de información o aclaración solicitadas por los accionistashttps://www.pharmaradar360.com/article/4382f798e5054aefPharmaRadar360en2026-05-05T22:06:56.000ZSolicitud de información mediante comunicación electrónicahttps://www.pharmaradar360.com/article/9accb35989608f83PharmaRadar360en2026-05-05T22:06:08.000ZDelegación de la representación y voto mediante comunicación electrónicahttps://www.pharmaradar360.com/article/c47345cdd4b9bafaPharmaRadar360en2026-05-05T22:05:22.000ZAcceso asistencia telemática Junta General Ordinaria de Accionistas 2026https://www.pharmaradar360.com/article/ef6adc3241c3f5f3PharmaRadar360en2026-05-05T22:04:26.000ZForo electrónico de accionistashttps://www.pharmaradar360.com/article/482eff96a4f53104PharmaRadar360en2026-05-05T22:03:36.000ZModelo de tarjeta de asistencia, delegación y voto a distanciahttps://www.pharmaradar360.com/article/bb3042b5538106aaPharmaRadar360en2026-05-05T22:02:52.000ZNúmero total de acciones y derechos de votohttps://www.pharmaradar360.com/article/f217940abeeb663fPharmaRadar360en2026-05-05T22:02:08.000ZReglas sobre solicitud de información previa a la Junta, representación y voto mediante medios de comunicación a distanciahttps://www.pharmaradar360.com/article/66479637af1b7ca1PharmaRadar360en2026-05-05T22:01:12.000ZInforme sobre la Independencia del Auditor de Cuentas y del Verificador de la información sobre sostenibilidad 2025https://www.pharmaradar360.com/article/34838094db964cbePharmaRadar360en2026-05-05T21:43:11.000ZDiplomado en Farmacología de los Tratamientos de las Enfermedades Infecciosas, Quimioterapéuticos y Vacunas», entre Asociación MÁS QUE FARMACIA y la Junta de Vigilancia de la Profesión Químico Farmacéutica (JVPQF)https://www.pharmaradar360.com/article/8e5db748754f62a4PharmaRadar360en2026-05-05T19:31:22.000ZInterfarma defende proibição de manipulação de medicamentos à base de GLP‑1